Plain-English translation of NCT05468073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 clinical trial testing whether a medication called ® (low-dose interleukin-2) can help slow or improve symptoms in people with early Alzheimer's disease. The study will compare the medication to a placebo (a dummy injection with no active drug) to see if the medication is safe and whether it helps protect memory and thinking abilities. You would have a 50/50 chance of receiving either the real medication or placebo.
Alzheimer's disease damages the brain by triggering unwanted inflammation and immune responses. Scientists believe that this medication, given at very low doses, might calm that harmful inflammation and help protect brain cells — something that current Alzheimer's treatments don't directly address.
You likely qualify if…
You likely don't qualify if…
Over 18 weeks, you would receive 21 injections under the skin — either the real medication or placebo. The first 5 injections happen on consecutive days, followed by a one-week break, then 16 more injections given weekly. Before treatment starts and again at the end, you'll have advanced brain scans (PET/MRI) to measure inflammation. You'll return for follow-up visits at 6, 12, and 18 months after starting treatment to check your memory and thinking abilities. Total involvement is about 18 months.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France